argenx SE/$ARGX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
- Ticker
- $ARGX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,863
- Headquarters
- Amsterdam, Netherlands
- Website
- argenx.com
argenx SE Metrics
BasicAdvanced
$55B
30.26
$28.88
-0.04
-
Price and volume
Market cap
$55B
Beta
-0.04
52-week high
$1,072.75
52-week low
$661.85
Average daily volume
429K
Financial strength
Total debt to equity
0.006
Interest coverage (TTM)
595.15%
Profitability
EBITDA (TTM)
1,901.067
Gross margin (TTM)
59.84%
Net profit margin (TTM)
31.73%
Operating margin (TTM)
31.94%
Effective tax rate (TTM)
1.14%
Revenue per employee (TTM)
$3,180,000
Management effectiveness
Valuation
Price to earnings (TTM)
30.257
Price to revenue (TTM)
9.189
Price to book
5.81
Price to tangible book (TTM)
6
Growth
Revenue change (TTM)
60.60%
Earnings per share change (TTM)
24.08%
3-year revenue growth (CAGR)
79.16%
10-year revenue growth (CAGR)
79.29%
3-year earnings per share growth (CAGR)
90.60%
What the Analysts think about argenx SE
Analyst ratings (Buy, Hold, Sell) for argenx SE stock.
Analyst projections of the future price of argenx SE stock.
Bulls say / Bears say
VYVGART product sales reached $1.5 billion in the second quarter, up 60% year on year and 17% from the previous quarter. That pace of growth supports the case that argenx is turning its lead medicine into a substantial commercial business. (argenx)
The FDA expanded VYVGART’s gMG label to cover all adult serotypes, including patients who test negative for AChR antibodies. This broadens the group of patients the company can target in its largest market. (argenx)
A Phase 3 study of VYVGART Hytrulo in autoimmune myositis met its primary endpoint, with a statistically significant and clinically meaningful improvement versus placebo. If the results support approval, myositis could add another use for the established drug franchise. (argenx)
Argenx stopped its Phase 3 Sjögren’s study after an interim review found it was unlikely to meet its primary endpoint. The failure removes a potential growth opportunity and highlights the risk in extending VYVGART into new diseases. (The Wall Street Journal)
The company spent $929 million on research and development in the first half of 2026, up from $600 million a year earlier. Such rising investment increases the pressure on its pipeline to deliver successful products and indications. (SEC)
The business remains heavily reliant on VYVGART: the company reported $2.8 billion in VYVGART sales in the first half, equal to its total product net sales. Any slowdown in uptake or loss of market share would therefore have a direct effect on the overall business. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2026.
argenx SE Financial Performance
Revenues and expenses
argenx SE Earnings Performance
Company profitability
Upcoming events
No upcoming events
argenx SE News
AllArticlesVideos
What argenex (ARGX) Said on Its Q3 Earnings Call
MarketBeat3 days ago
ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law
Business Wire2 weeks ago
argenx shares drop after trial of Vyvgart in Sjögren's disease is halted
Proactive Investors2 weeks ago
Funds containing argenx SE
AllUSDEURGBP
Fund name | Fund size | $ARGX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 1.57% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 1.57% |
Vanguard ESG Developed Europe All Cap£V3EL | €35M | 0.56% |
Vanguard ESG Developed Europe All Cap£V3EA | €125M | 0.56% |
Vanguard FTSE Developed Europe ex UK€VERX | €3.3B | 0.54% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.